In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
In the latest session, Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) closed at $46.89 down -4.03% from its previous closing price of $48.86. In other words, the price has decreased by -$4.03 from its previous closing price. On the day, 0.75 million shares were traded. RARE stock price reached its highest trading level at $49.15 during the session, while it also had its lowest trading level at $46.11.
Ratios:
For a deeper understanding of Ultragenyx Pharmaceutical Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.65 and its Current Ratio is at 2.81. In the meantime, Its Debt-to-Equity ratio is 2.63 whereas as Long-Term Debt/Eq ratio is at 2.46.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Goldman on June 06, 2024, Upgraded its rating to Buy and sets its target price to $67 from $56 previously.
On April 22, 2024, RBC Capital Mkts started tracking the stock assigning a Outperform rating and target price of $77.
On December 08, 2023, Wells Fargo started tracking the stock assigning a Overweight rating and target price of $72.Wells Fargo initiated its Overweight rating on December 08, 2023, with a $72 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Dec 10 ’24 when KAKKIS EMIL D sold 8,273 shares for $50.00 per share. The transaction valued at 413,650 led to the insider holds 2,195,712 shares of the business.
KAKKIS EMIL D bought 8,273 shares of RARE for $413,650 on Dec 10 ’24. On Oct 10 ’24, another insider, Horn Howard, who serves as the Chief Financial Officer of the company, sold 7,465 shares for $52.76 each. As a result, the insider received 393,853 and left with 92,301 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RARE now has a Market Capitalization of 4511943168 and an Enterprise Value of 4638780928. For the stock, the TTM Price-to-Sale (P/S) ratio is 8.28 while its Price-to-Book (P/B) ratio in mrq is 12.47. Its current Enterprise Value per Revenue stands at 8.874 whereas that against EBITDA is -9.258.
Stock Price History:
Over the past 52 weeks, RARE has reached a high of $60.37, while it has fallen to a 52-week low of $37.02. The 50-Day Moving Average of the stock is -7.59%, while the 200-Day Moving Average is calculated to be -2.50%.
Shares Statistics:
For the past three months, RARE has traded an average of 706.89K shares per day and 549130 over the past ten days. A total of 92.24M shares are outstanding, with a floating share count of 83.32M. Insiders hold about 9.77% of the company’s shares, while institutions hold 92.12% stake in the company. Shares short for RARE as of 1732838400 were 3379045 with a Short Ratio of 4.78, compared to 1730332800 on 3179627. Therefore, it implies a Short% of Shares Outstanding of 3379045 and a Short% of Float of 4.2.
